˶ News Release
/index.html
View the latest ˶ Co., Ltd. news releases.EISAI RECOGNIZED AS “2025 KENKO INVESTMENT FOR HEALTH” FOR THE FIRST TIME AND CERTIFIED AS “OUTSTANDING ORGANIZATION OF KENKO INVESTMENT FOR HEALTH PROGRAM (WHITE 500)” FOR THE SIXTH TIME
/news/2025/news202520.html
˶'s news release EISAI RECOGNIZED AS “2025 KENKO INVESTMENT FOR HEALTH” FOR THE FIRST TIME AND CERTIFIED AS “OUTSTANDING ORGANIZATION OF KENKO INVESTMENT FOR HEALTH PROGRAM (WHITE 500)” FOR THE SIXTH TIME is posted. 2025-03-10T15:40:00+09:00˶ Announces Appointments of Corporate Officers
/news/2025/news202519.html
˶'s news release ˶ Announces Appointments of Corporate Officers is posted. 2025-03-07T17:05:00+09:00Notice of Nominees for Directors
/news/2025/news202518.html
˶'s news release Notice of Nominees for Directors is posted. 2025-03-07T17:05:00+09:00Notification Regarding Changes in Representative Corporate Officers
/news/2025/news202517.html
˶'s news release Notification Regarding Changes in Representative Corporate Officers is posted. 2025-03-07T17:05:00+09:00UPDATE ON THE CO-PROMOTION OF THE ORAL ANTIFUNGAL AGENT NAILIN® CAPSULES 100MG IN JAPAN
/news/2025/news202516.html
˶'s news release UPDATE ON THE CO-PROMOTION OF THE ORAL ANTIFUNGAL AGENT NAILIN® CAPSULES 100MG IN JAPAN is posted. 2025-03-04T10:00:00+09:00˶ Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia
/news/2025/news202515.html
˶'s news release ˶ Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia is posted. 2025-03-03T16:40:00+09:00“Fatigue Recovery While You Sleep!” ˶ to Launch Designated Quasi-Drug Drink “Chocola BB® Nightwell”
/news/2025/news202514.html
˶'s news release “Fatigue Recovery While You Sleep!” ˶ to Launch Designated Quasi-Drug Drink “Chocola BB® Nightwell” is posted. 2025-03-03T10:00:00+09:00The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s Disease
/news/2025/news202513.html
˶'s news release The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s Disease is posted. 2025-02-28T19:33:44+09:00˶ Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
/news/2025/news202512.html
˶'s news release ˶ Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone is posted. 2025-02-28T09:00:00+09:00EISAI SELECTED FOR “HUMAN CAPITAL LEADERS 2024” AND “HUMAN CAPITAL MANAGEMENT GOLD QUALITY” FOR SECOND CONSECUTIVE YEAR, AS A COMPANY COMMITTED TO EXCELLENT MANAGEMENT AND DISCLOSURE OF HUMAN CAPITAL INITIATIVES
/news/2025/news202511.html
˶'s news release EISAI SELECTED FOR “HUMAN CAPITAL LEADERS 2024” AND “HUMAN CAPITAL MANAGEMENT GOLD QUALITY” FOR SECOND CONSECUTIVE YEAR, AS A COMPANY COMMITTED TO EXCELLENT MANAGEMENT AND DISCLOSURE OF HUMAN CAPITAL INITIATIVES is posted. 2025-02-20T11:35:00+09:00DEVELOPMENT OF PREDICTION MODEL FOR BRAIN AMYLOID-BETA ACCUMULATION FOR EARLY SCREENING OF ALZHEIMER’S DISEASE
/news/2025/news202510.html
˶'s news release DEVELOPMENT OF PREDICTION MODEL FOR BRAIN AMYLOID-BETA ACCUMULATION FOR EARLY SCREENING OF ALZHEIMER’S DISEASE is posted. 2025-02-14T11:00:00+09:00˶ Rated “A”, the Highest Rating by CDP in the Categories of Climate Change and Water Security
/news/2025/news202509.html
˶'s news release ˶ Rated “A”, the Highest Rating by CDP in the Categories of Climate Change and Water Security is posted. 2025-02-06T16:35:37+09:00˶ to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
/news/2025/news202508.html
˶'s news release ˶ to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies is posted. 2025-02-03T10:00:00+09:00Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
/news/2025/news202507.html
˶'s news release Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union is posted. 2025-01-31T20:30:00+09:00FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
/news/2025/news202506.html
˶'s news release FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease is posted. 2025-01-27T08:30:00+09:00